Efonidipine hydrochloride ethanolate

CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.

CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.

CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.

CI-1033 is a potent, irreversible ATP binding site–directed pan-ErbB tyrosine kinase inhibitor with IC50 in the low nanomolar range for EGFR, HER2, and ErbB-4.

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

An internal standard for the quantification of EPEA by GC- or LC-MS.

A bottle containing 950mL of eosin Y solution in a 1% alcoholic formulation, utilized in histological staining as a counterstain to hematoxylin, providing contrast and aiding in the visualization of tissue structures under microscopy.

ETHANOLAMINE SUITABLE FOR USE AS EXCIPIENT EMPROVE(R) EXP BP NF

ETHANOLAMINE SUITABLE FOR USE AS EXCIPIENT EMPROVE(R) EXP BP NF

CAS No.: 628-97-7 Solubility: (20°C) insoluble Melting Point: 23 - 26°C Molar Mass: 284.48 g/mol Boiling Point: 192 - 194°C (13 hPa) Flash Point: 164°C Refractive Index: 164°C Density: 0.86 g/cm3 (20°C)

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the